SynthesisFrontiers in oncology2026
Glioma management and outcome in low-middle-income countries: a systematic review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are the most common primary malignant brain tumors, yet evidence on their management and outcomes in low- and middle-income countries (LMICs) remains limited. Disparities in diagnostic capacity, treatment access, and healthcare infrastructure create unique challenges that are poorly characterized in the existing literature. Method: A systematic review was conducted following PRISMA guidelines and registered in PROSPERO (CRD420261359813). PubMed and Scopus were searched for studies reporting glioma management and outcomes in LMICs. Two independent reviewers performed screening, data extraction, and quality assessment using the Newcastle-Ottawa Scale. Results: Thirty studies comprising 3,463 patients from 17 low- and middle-income countries (LMICs) were included. Low-grade gliomas accounted for 62.6% of tumors, while high-grade gliomas represented 37.4%. Molecular profiling was reported in 26.7% of studies. LGGs showed significantly better outcomes than HGGs, with pooled 5-year OS rates of 87.8% and 21.9%, respectively. Conclusion: Glioma management in LMICs is characterized by limited access to adjuvant therapies, minimal molecular diagnostic integration, and heterogeneous survival outcomes that fall below standards achieved in high-income countries. Targeted investments in radiotherapy infrastructure, chemotherapy access, and molecular diagnostic capabilities are essential to reduce global disparities in neuro-oncological care. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD420261359813.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.